Merck KGaA Agrees to Acquire SpringWorks for $3.9 Billion
Merck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreIn a transformative move for the U.S. healthcare manufacturing sector, Roche unveiled plans to invest $50 billion in American pharmaceutical
Read moreEli Lilly and Company announced groundbreaking Phase 2 results for its investigational siRNA therapy lepodisiran, which reduced lipoprotein(a) [Lp(a)] levels
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreAs we approach the midpoint of the 2020s, the pharmaceutical industry has undergone a radical digital transformation, driven by the
Read moreNovartis has received its third U.S. Food and Drug Administration (FDA) approval for Fabhalta® (iptacopan), marking a major milestone as
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read moreResearchers and scientists worldwide can now access Evo 2, a massive new foundation model that deciphers the genetic code across
Read moreAmerican multinational pharma company Incyte and AI-focused biotech Genesis Therapeutics have announced a strategic collaboration to leverage artificial intelligence for
Read moreViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, announced today that
Read more